Ngl Fine Chem Ltd
NGLFINENgl Fine Chem Ltd
NGLFINEPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
38.83 | 7.21 | 0.07% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
NGL Fine-Chem Limited is manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 96.49 | 101.15 | 116.23 | 157.29 | 154.74 | 265.99 | 328.18 | 283.61 | 352.82 | 352.83 | ||||||||||
Raw Materials | 39.09 | 38.28 | 50.38 | 65.29 | 71.02 | 102.62 | 172.27 | 118.75 | 285.42 | 285.41 | ||||||||||
Power & Fuel Cost | 3.94 | 4.18 | 5.87 | 8.71 | 9.99 | 9.85 | 15.86 | 18.27 | ||||||||||||
Employee Cost | 11.35 | 13.85 | 18.37 | 21.16 | 24.04 | 28.09 | 34.85 | 36.87 | ||||||||||||
Selling & Administrative Expenses | 9.70 | 4.88 | 5.81 | 10.22 | 8.00 | 11.62 | 8.69 | 11.55 | ||||||||||||
Operating & Other expenses | 10.25 | 13.06 | 11.67 | 15.50 | 18.87 | 25.69 | 17.64 | 57.68 | ||||||||||||
EBITDA | 22.16 | 26.90 | 24.13 | 36.41 | 22.82 | 88.12 | 78.87 | 40.49 | 67.40 | 67.42 | ||||||||||
Depreciation/Amortization | 2.72 | 3.08 | 4.56 | 6.30 | 8.11 | 8.33 | 10.37 | 11.29 | 11.64 | 11.61 | ||||||||||
PBIT | 19.44 | 23.82 | 19.57 | 30.11 | 14.71 | 79.79 | 68.50 | 29.20 | 55.76 | 55.81 | ||||||||||
Interest & Other Items | 1.57 | 1.00 | 1.77 | 2.55 | 2.63 | 2.20 | 1.91 | 1.83 | 1.34 | 1.37 | ||||||||||
PBT | 17.87 | 22.82 | 17.80 | 27.56 | 12.08 | 77.59 | 66.59 | 27.37 | 54.42 | 54.44 | ||||||||||
Taxes & Other Items | 6.47 | 7.93 | 5.21 | 7.44 | 3.73 | 20.87 | 16.70 | 6.87 | 13.11 | 13.10 | ||||||||||
Net Income | 11.40 | 14.89 | 12.59 | 20.12 | 8.35 | 56.72 | 49.89 | 20.50 | 41.31 | 41.34 | ||||||||||
EPS | 18.45 | 24.10 | 20.38 | 32.57 | 13.52 | 91.81 | 80.75 | 33.18 | 66.88 | 66.91 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.05 | 0.13 | 0.02 | 0.02 | 0.05 | 0.03 | 0.03 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Ngl Fine Chem Ltd | 38.86 | 7.21 | 0.07% |
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare NGLFINE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
NGLFINE has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.67 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹1.75
Ex DateEx Date
Aug 16, 2024
Past Dividends
Cash Dividend
Ex DateEx DateAug 18, 2023
Dividend/Share
₹1.75
Ex DateEx Date
Aug 18, 2023
Cash Dividend
Ex DateEx DateJun 22, 2022
Dividend/Share
₹1.75
Ex DateEx Date
Jun 22, 2022
Cash Dividend
Ex DateEx DateAug 12, 2021
Dividend/Share
₹1.75
Ex DateEx Date
Aug 12, 2021
Cash Dividend
Ex DateEx DateAug 6, 2020
Dividend/Share
₹1.75
Ex DateEx Date
Aug 6, 2020
Cash Dividend
Ex DateEx DateAug 13, 2019
Dividend/Share
₹1.75
Ex DateEx Date
Aug 13, 2019
NGL Fine Chem soars 13% on strong operational performance in Q4
Biofil Chemicals & Pharmaceuticals Ltd leads gainers in ‘B’ group
NGL Fine Chem consolidated net profit declines 66.43% in the September 2022 quarter
NGL Fine Chem standalone net profit declines 65.05% in the September 2022 quarter
NGL Fine Chem standalone net profit declines 45.07% in the March 2022 quarter
NGL Fine Chem consolidated net profit declines 50.36% in the March 2022 quarter
NGL Fine Chem Consolidated December 2021 Net Sales at Rs 81.37 crore, up 11.89% Y-o-Y
NGL Fine Chem sheds 15% after profit slumps in Q3
NGL Fine Chem completes expansion work at subsidiary’s plant
NGL Fine Chem consolidated net profit declines 12.02% in the September 2021 quarter
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.54%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 0.07% to 0.1%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 15.47%, vs industry avg of 15.15%